Special Considerations in the Management of HIV-Infected Patients From Minority Communities
Summary
- SPRING-2 trial compared dolutegravir with raltegravir in treatment-naive patients receiving coformulated emtricitabine/tenofovir DF or abacavir/lamivudine[Raffi 2013]
- SINGLE trial compared dolutegravir plus coformulated abacavir/lamivudine with efavirenz/emtricitabine/tenofovir DF in treatment-naive patients[Walmsley 2013]
- Efficacy of the dolutegravir-based regimens was similar across racial groups[Raffi 2015]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content